PETHEMA Foundation: Leukemia trials

The registry lists 37 Leukemia studies with PETHEMA Foundation as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 5Phase 2 10Phase 3 4Phase 4 14No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treatment Protocol for Newky Diagnosed Adult Ph Positive ALLNot yet recruitingNCT06175702
• A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic MarkersCompletedNCT05541224
• Molecular Diagnostic Platform for AMLStatus unknownNCT04446741
• Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
• A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
• Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
• REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
• Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
• Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
• VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 YearsCompletedNCT02606825
• CML Treated With Bosutinib After RelapseCompletedNCT02445742Phase 2
• Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02319135Phase 3
• Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaCompletedNCT02036489Phase 4
• Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseStatus unknownNCT01802450Phase 2
• Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTSCompletedNCT01540812
• Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
• Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
• Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 YearsStatus unknownNCT01376427Not applicable
• Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)Status unknownNCT01366898Phase 4
• PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 YearsStatus unknownNCT01296178Not applicable
• LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
• PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic LeukemiaTerminatedNCT00944008Phase 3
• Treatment of High Risk Adult Acute Lymphoblastic LeukemiaCompletedNCT00853008Phase 4
• Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
• Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
• LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic LeukemiaCompletedNCT00526409Phase 4
• LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia PositiveCompletedNCT00526305Phase 4
• Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)CompletedNCT00504764Phase 4
• PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaCompletedNCT00494897Phase 4
• Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
• SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
• Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 YearsCompletedNCT00464217Phase 4
• Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)CompletedNCT00408278Phase 4
• Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary AspergillosisCompletedNCT00391014Phase 2
• Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid LeukaemiaCompletedNCT00390897Phase 4
• Treatment of Acute Myeloblastic Leukemia in Younger PatientsCompletedNCT00390715
• Glivec in Ph Positive Lymphoblastic LeukemiaCompletedNCT00388895Phase 2